Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

645
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
645
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

252
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
252
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Research progress on potential high-risk drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining.

Frontiers in pharmacology·2026
Same author

Mesenchymal Stromal Cell-Derived Extracellular Vesicles Mediate Mitochondrial Delivery in Injury: Mechanistic Insights, Evidentiary Tiers, and Translational Challenges.

Stem cell reviews and reports·2026
Same author

Evaluating the association between intravenous immunoglobulin and thromboembolic events in patients with autoimmune diseases: a retrospective real-world study.

Frontiers in pharmacology·2026
Same author

Revealing bond level origin of stability in disordered solids from marginal stability to ultrastability.

Nature communications·2026
Same author

DGrA: Lightweight Modulation Recognition Based on Hybrid Neural Networks.

Sensors (Basel, Switzerland)·2026
Same author

Impact of Hospital Hierarchy on Nurses' Attitudes Toward Artificial Intelligence: Mediating Roles of Artificial Intelligence Literacy and Anxiety.

Journal of nursing management·2026

相关实验视频

Updated: Sep 10, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

以CYP2C19基因型为指导的抗血小板治疗,以预防未破裂的内动脉瘤在支架辅助的线圈栓塞后发生的血栓栓塞事件:一项回顾性队列研究

Mingdong Yang1, Xiaoyu Zhang1, Junjun Xu1

  • 1Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.

Journal of neurointerventional surgery
|August 24, 2025
PubMed
概括

在未破裂的内动脉瘤中,CYP2C19基因型导向的抗血小板治疗显著降低了支架辅助卷积后的缺血事件. 这种个性化的方法提高了安全性, 没有增加出血的风险.

关键词:
动脉瘤一种药物遗传学

更多相关视频

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

49
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K

相关实验视频

Last Updated: Sep 10, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

49
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K

科学领域:

  • 神经干预手术
  • 药物基因组学
  • 心血管医学

背景情况:

  • 已确定CYP2C19的基因定型,用于指导心血管疾病的抗血小板治疗.
  • 在神经干预手术中,尤其是未破裂的内动脉瘤 (UIA) 中,它的实用性较少.
  • 这项研究研究了用CYP2C19指导的治疗后,用于UIA的支架辅助线圈栓塞 (SAC).

研究的目的:

  • 评估由CYP2C19指导的抗血小板治疗的临床效用.
  • 评估其对UIA患者SAC后的术后管理的影响.

主要方法:

  • 分析了403名接受SAC治疗的患者.
  • 对照组 (n=220) 接受了标准的双抗血小板治疗 (DAPT).
  • 基因型指导组 (n=183) 根据CYP2C19代谢器状态获得个性化的DAPT.

主要成果:

  • 脑内缺血事件发生在对照组的10. 9%,而基因型指导组的4. 9% (54. 9%的相对风险降低,P=0. 029).
  • 系统性出血事件发生在对照组的4. 5%,基因型指导组的6. 6% (P=0. 388),没有显著差异.

结论:

  • 用CYP2C19指导的抗血小板治疗显著降低了UIA发生后内缺血事件的风险.
  • 这种方法不会增加全身出血并发症.
  • 基因型导向治疗为神经干预提供了潜在的更安全和更有效的外科手术策略.